Loading
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (39 ops.)
Latest filing published 16 Oct 2026 for Gilead Sciences, INC., €418k.
Filing timeline
BuySaleJohanna Mercier
Insider track record
Disclosed buys
0
Disclosed sells
39
Signal history
Johanna Mercier: trading record in brief
Johanna Mercier made 37 open-market sales at Gilead Sciences, Inc., for EUR 23.6 million and a median of EUR 340,726. The three largest are dated November 17, 2025 (EUR 2,765,036), February 17, 2026 (EUR 2,394,692) and August 17, 2026 (EUR 1,960,247). No purchase is on record.
The 113 filings, published between July 28, 2020 and October 16, 2026, are split between Gilead Sciences, Inc. (111, "Chief Commercial Officer") and Neurocrine Biosciences Inc (2, "Director"). The record holds 40 grants and 36 option exercises. The yearly volume goes from 4 filings in 2020 to 14 in 2023, 19 in 2024, 30 in 2025 and 28 in 2026. The last 12 months hold 34 filings, 19 of them sales. Publication follows the trade by a median of 1 day.
At Gilead Sciences, Inc., 32 trades by Johanna Mercier fall within 30 days of a trade by Andrew D. Dickinson, 27 for Daniel Patrick O'Day and 15 for Jeffrey Bluestone, all in the same direction.
Companies and markets linked to Johanna Mercier
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations113 total
3,000 shares@ US$156.220.0002% mcap2.6% of flowCommon StockSEC:0001782135-26-000035:0
1,600 shares@ US$143.69170.0001% mcap1.1% of flowCommon StockSEC:0001782135-26-000033:0
800 shares@ US$144.45690.0001% mcap0.5% of flowCommon StockSEC:0001782135-26-000033:1
600 shares@ US$145.290.0000% mcap0.4% of flowCommon StockSEC:0001782135-26-000033:2
2,797 sharesCommon StockSEC:0001782135-26-000031:0
1,347 shares@ US$144.810.0001% mcap0.9% of flowCommon StockSEC:0001782135-26-000031:1
1,890 shares@ US$72.340.0001% mcap0.7% of flowCommon StockSEC:0001782135-26-000028:1
16,530 shares@ US$137.3650.0012% mcap12.4% of flowCommon StockSEC:0001782135-26-000028:2
23,110 shares@ US$66.640.0008% mcap8.4% of flowCommon StockSEC:0001782135-26-000028:0
11,470 shares@ US$138.03530.0008% mcap8.7% of flowCommon StockSEC:0001782135-26-000028:3
3,000 shares@ US$129.91920.0002% mcap2.2% of flowCommon StockSEC:0001782135-26-000026:0
450 shares@ US$125.400.3% of flowCommon StockSEC:0001782135-26-000024:2
1,480 shares@ US$123.41660.9% of flowCommon StockSEC:0001782135-26-000024:0
1,070 shares@ US$123.99580.7% of flowCommon StockSEC:0001782135-26-000024:1
2,796 sharesCommon StockSEC:0001782135-26-000022:0
1,341 sharesCommon StockSEC:0001782135-26-000022:1
3,000 shares@ US$140.960.0002% mcap2.3% of flowCommon StockSEC:0001782135-26-000014:0
3,000 shares@ US$144.230.0002% mcap2.4% of flowCommon StockSEC:0001782135-26-000012:0
3,216 shares@ US$148.560.9% of flowCommon StockSEC:0001782135-26-000010:1
6,617 sharesCommon StockSEC:0001782135-26-000010:0
11,090 shares0Common StockSEC:0001782135-26-000008:0
18,405 shares@ US$154.185.4% of flowCommon StockSEC:0001782135-26-000006:1
9,395 shares@ US$154.912.8% of flowCommon StockSEC:0001782135-26-000006:2
200 shares@ US$155.620.1% of flowCommon StockSEC:0001782135-26-000006:3
25,000 shares@ US$66.648.9% of flowCommon StockSEC:0001782135-26-000006:0
25 of 113 declarations
